Intellia Therapeutics Reports $106.6 Million Net Loss in Q2 2026, Collaboration Revenue Declines

Intellia Therapeutics, Inc. reported a net loss of $106.6 million for the second quarter of 2026, compared to a net loss of $101.3 million in the same period last year. The company's collaboration revenue decreased to $7.7 million from $14.2 million year-over-year, primarily due to reduced revenue from its collaboration with Regeneron Pharmaceuticals. Total operating expenses for the quarter were $120.4 million, a slight decrease from $124.2 million in the prior year, driven by a reduction in research and development costs, which fell to $82.6 million from $97.0 million. General and administrative expenses, however, increased to $37.8 million from $27.2 million, reflecting higher legal and consulting costs associated with the company's commercial infrastructure buildout.

For the first half of 2026, Intellia's net loss was $202.9 million, an improvement from a loss of $215.6 million in the same period of 2025. Collaboration revenue for the six months ended June 30, 2026, was $22.7 million, down from $30.9 million in the previous year. The decrease in revenue was attributed to a reduction in milestone payments and material shipments under the Regeneron collaboration. Research and development expenses also decreased significantly, totaling $163.3 million compared to $205.5 million in the prior year, as the company focused on its lead product candidates, lonvoguran ziclumeran (lonvo-z) and nexiguran ziclumeran (nex-z).

Intellia's cash, cash equivalents, and marketable securities totaled $628.4 million as of June 30, 2026, bolstered by a follow-on public offering that generated net proceeds of $194.6 million in April 2026. The company has indicated that its current financial resources will support its operations and capital expenditures through at least 2028, excluding potential milestone payments from collaborations. The company continues to advance its clinical programs, with lonvo-z expected to launch commercially in the first half of 2027, pending regulatory approval.

Operationally, Intellia is preparing for the commercial launch of lonvo-z, which has shown promising results in clinical trials for hereditary angioedema. The company is also advancing its nex-z program for transthyretin amyloidosis, with patient enrollment in ongoing Phase 3 trials expected to complete in the second half of 2026. The company has made significant progress in its clinical development pipeline, focusing on leveraging its CRISPR gene editing technology to address severe diseases.

Looking ahead, Intellia remains focused on executing its clinical development strategy while managing costs effectively. The company aims to continue building its commercial capabilities and expanding its pipeline through strategic collaborations. The outlook remains cautiously optimistic, with the potential for significant advancements in its product candidates and the overall therapeutic landscape.